Tumor Site-Dependent Transport Properties Determine Nanotherapeutics Delivery and Its Efficacy

Insufficient delivery of systemically administered anticancer drugs to tumors can compromise therapeutic efficacy and develop drug delivery-based therapeutic resistance. Nanotherapeutics such as PEGylated liposomal doxorubicin (PLD) are designed to preferentially accumulate in tumors utilizing enhan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kai, Megumi, Ziemys, Arturas, Liu, Yan ting, Kojic, Milos, Ferrari, Mauro, Yokoi, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600803/
https://www.ncbi.nlm.nih.gov/pubmed/31228770
http://dx.doi.org/10.1016/j.tranon.2019.05.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600803/
https://www.ncbi.nlm.nih.gov/pubmed/31228770
http://dx.doi.org/10.1016/j.tranon.2019.05.011

Ejemplares similares